LMH STRATEGIC SOLUTIONS

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · Massachusetts · House · Senate · $30,000.00 income · posted Jul 15, 2025

Bills named in this filing 3

Lobbying activity 1

Medicare/Medicaid

General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. PRV.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.